Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

被引：0
|
作者：
Li, Y. [1 ]
Chen, Z. [2 ]
Wu, L. [1 ]
Tao, W. [1 ]
机构：
[1] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Tumor Mutation Score; Tumor Mutation Burden; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-40
引用
收藏
页码：S724 / S724
页数：1
相关论文
共 50 条
  • [21] Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
    Schatz, Stefanie
    Falk, Markus
    Jori, Balazs
    Ramdani, Hayat O.
    Schmidt, Stefanie
    Willing, Eva-Maria
    Menon, Roopika
    Groen, Harry J. M.
    Diehl, Linda
    Kroeger, Matthias
    Wesseler, Claas
    Griesinger, Frank
    Hoffknecht, Petra
    Tiemann, Markus
    Heukamp, Lukas C.
    CANCERS, 2020, 12 (06) : 1 - 14
  • [22] The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age
    Wu, Yongfeng
    Xu, Jinming
    Xu, Jiawei
    Wang, Yiqing
    Wang, Luming
    Lv, Wang
    Hu, Jian
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [23] Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab
    Park, W.
    Lopes, G.
    Kwon, D.
    Florou, V.
    Chae, Y. K.
    Warsch, J.
    Ishkanian, A.
    Jahanzeb, M.
    Mudad, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2004 - S2005
  • [24] PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis
    Deng, Hongsheng
    Zhao, Yi
    Cai, Xiuyu
    Chen, Hualin
    Cheng, Bo
    Zhong, Ran
    Li, Feng
    Xiong, Shan
    Li, Jianfu
    Liu, Jun
    He, Jianxing
    Liang, Wenhua
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 170
  • [25] Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy
    Oh, Michael S.
    Abascal, Jensen
    Rennels, Austin K.
    Salehi-Rad, Ramin
    Dubinett, Steven M.
    Liu, Bin
    CANCERS, 2025, 17 (06)
  • [26] DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
    Li, Man
    Lin, Anqi
    Luo, Peng
    Shen, Weitao
    Xiao, Dan
    Gou, Lanying
    Zhang, Jian
    Guo, Linlang
    AGING-US, 2020, 12 (02): : 1285 - 1303
  • [27] Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
    Park, Sehhoon
    Lee, Chung
    Ku, Bo Mi
    Kim, Minjae
    Park, Woong-Yang
    Kim, Nayoung K. D.
    Ahn, Myung-Ju
    BMB REPORTS, 2021, 54 (07) : 386 - 391
  • [28] Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
    Chen, Hao
    Chong, Wei
    Wu, Qian
    Yao, Yueliang
    Mao, Min
    Wang, Xin
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [29] Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer
    Wang, Yuchang
    Chen, Rui
    Wa, Yue
    Ding, Shikuan
    Yang, Yijian
    Liao, Junbo
    Tong, Lei
    Xiao, Gelei
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
    Chae, Young Kwang
    Davis, Andrew A.
    Agte, Sarita
    Pan, Alan
    Simon, Nicholas I.
    Iams, Wade T.
    Cruz, Marcelo R.
    Tamragouri, Keerthi
    Rhee, Kyunghoon
    Mohindra, Nisha
    Villaflor, Victoria
    Park, Wungki
    Lopes, Gilberto
    Giles, Francis J.
    ONCOLOGIST, 2019, 24 (06) : 820 - 828
12345